1. Peritumoral indoleamine 2, 3‐dioxygenase expression in melanoma: an early marker of resistance to immune control?. (1st November 2014) Authors: Chevolet, I.; Speeckaert, R.; Haspeslagh, M.; Neyns, B.; Krüse, V.; Schreuer, M.; Van Gele, M.; Van Geel, N.; Brochez, L. Journal: British journal of dermatology Issue: Volume 171:Number 5(2014:Nov.) Page Start: 987 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Peritumoral indoleamine 2, 3‐dioxygenase expression in melanoma: an early marker of resistance to immune control?. (6th October 2014) Authors: Chevolet, I.; Speeckaert, R.; Haspeslagh, M.; Neyns, B.; Krüse, V.; Schreuer, M.; Van Gele, M.; Van Geel, N.; Brochez, L. Journal: British journal of dermatology Issue: Volume 171:Number 5(2014:Nov.) Page Start: 987 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Peritumoral indoleamine 2, 3‐dioxygenase expression in melanoma: an early marker of resistance to immune control?. (6th October 2014) Authors: Chevolet, I.; Speeckaert, R.; Haspeslagh, M.; Neyns, B.; Krüse, V.; Schreuer, M.; Van Gele, M.; Van Geel, N.; Brochez, L. Journal: British journal of dermatology Issue: Volume 171:Number 5(2014:Nov.) Page Start: 987 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗